Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-4055 + Sorafenib in Metastatic Melanoma
NCT00498836Phase 2Completed
- Sponsor
- Clavis Pharma
- Start
- Mar 2007
- Primary completion
- Oct 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of elacytarabine in Malignant Melanoma (MM), sponsored by Clavis Pharma. Primary endpoint: Objective Tumor Response. Started Mar 2007; status: completed.
02
Drugs
elacytarabine
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00498836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498836.